MANAGEMENT OF ADVERSE EVENTS ASSOCIATED WITH CABOZANTINIB PLUS NIVOLUMAB IN ADVANCED RENAL CELL CARCINOMA

被引：0
|
作者：
Seery, Virginia [1 ]
Andresen, Diane [2 ]
Martone, Brenda [3 ]
Lee-Ramos, Steven [4 ]
Hall, Tasha [5 ]
Virdee, Kiran [6 ]
机构：
[1] Harvard Med Sch, Teaching Hosp, Beth Israel Deaconess Med Ctr, Boston, MA USA
[2] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[3] Northwestern Med, Robert H Lurie Canc Ctr, Chicago, IL USA
[4] Univ Calif San Francisco, Gastro Intestinal Med Oncol Clin, San Francisco, CA USA
[5] Exelixis Inc, Alameda, CA USA
[6] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
ONCOLOGY NURSING FORUM | 2024年 / 51卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
I37
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review
    McGregor, Bradley
    Mortazavi, Amir
    Cordes, Lisa
    Salabao, Cristina
    Vandlik, Susan
    Apolo, Andrea B.
    CANCER TREATMENT REVIEWS, 2022, 103
  • [2] Nivolumab plus cabozantinib for advanced renal cell carcinoma
    Benjamin, David J.
    Nolla, Kyle
    Cella, David
    FUTURE ONCOLOGY, 2022, 18 (39) : 4351 - 4359
  • [3] Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma
    Markham, Anthony
    TARGETED ONCOLOGY, 2022, 17 (02) : 193 - 201
  • [4] Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma
    Anthony Markham
    Targeted Oncology, 2022, 17 : 193 - 201
  • [5] Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma
    Schmidinger, Manuela
    Danesi, Romano
    ONCOLOGIST, 2018, 23 (03): : 306 - 315
  • [6] Adverse Events of Cabozantinib Plus Nivolumab Versus Plus Nivolumab
    Blas, Leandro
    Shiota, Masaki
    Tsukahara, Shigehiro
    Nagakawa, Shohei
    Matsumoto, Takashi
    Eto, Masatoshi
    CLINICAL GENITOURINARY CANCER, 2024, 22 (01) : e122 - e127.e1
  • [7] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Choueiri, T. K.
    Powles, T.
    Burotto, M.
    Escudier, B.
    Bourlon, M. T.
    Zurawski, B.
    Juarez, V. M. Oyervides
    Hsieh, J. J.
    Basso, U.
    Shah, A. Y.
    Suarez, C.
    Hamzaj, A.
    Goh, J. C.
    Barrios, C.
    Richardet, M.
    Porta, C.
    Kowalyszyn, R.
    Feregrino, J. P.
    Zolnierek, J.
    Pook, D.
    Kessler, E. R.
    Tomita, Y.
    Mizuno, R.
    Bedke, J.
    Zhang, J.
    Maurer, M. A.
    Simsek, B.
    Ejzykowicz, F.
    Schwab, G. M.
    Apolo, A. B.
    Motzer, R. J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09): : 829 - 841
  • [8] Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma
    Geynisman, Daniel M.
    Burotto, Mauricio
    Porta, Camillo
    Suarez, Cristina
    Bourlon, Maria T.
    Huo, Stephen
    Del Tejo, Viviana
    Du, Ella X.
    Yang, Xiaoran
    Betts, Keith A.
    Choueiri, Toni K.
    McGregor, Bradley
    CLINICAL DRUG INVESTIGATION, 2022, 42 (07) : 611 - 622
  • [9] Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma
    Daniel M. Geynisman
    Mauricio Burotto
    Camillo Porta
    Cristina Suarez
    Maria T. Bourlon
    Stephen Huo
    Viviana Del Tejo
    Ella X. Du
    Xiaoran Yang
    Keith A. Betts
    Toni K. Choueiri
    Bradley McGregor
    Clinical Drug Investigation, 2022, 42 : 611 - 622
  • [10] New EMA approval: Nivolumab plus Cabozantinib for advanced renal clear cell carcinoma
    Naoun, Natacha
    Vano, Yann-Alexandre
    BULLETIN DU CANCER, 2021, 108 (11) : 991 - 993
12345